{"id":"indium-111-pentetreotide","safety":{"commonSideEffects":[{"rate":null,"effect":"Flushing"},{"rate":null,"effect":"Abdominal pain"},{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Nausea"}]},"_chembl":{"chemblId":"CHEMBL1200642","moleculeType":"Protein","molecularWeight":"1502.48"},"_dailymed":{"setId":"e2117bbd-9db3-4d20-a5da-89551c18a0cb","title":"KIT FOR THE PREPARATION OF INDIUM IN 111 PENTETREOTIDE (INDIUM IN-111 PENTETREOTIDE) KIT [SUN PHARMACEUTICAL INDUSTRIES, INC.]"},"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Pentetreotide is a synthetic octapeptide that mimics somatostatin and binds with high affinity to somatostatin receptors (particularly subtypes 2 and 5) that are overexpressed on neuroendocrine tumors. When labeled with the gamma-emitting radioisotope Indium-111, it enables single-photon emission computed tomography (SPECT) imaging to detect and localize somatostatin receptor-positive tumors throughout the body. This allows clinicians to identify primary tumors, metastases, and assess receptor expression for potential therapeutic targeting.","oneSentence":"Indium-111 pentetreotide is a radiolabeled somatostatin analog that binds to somatostatin receptors on neuroendocrine tumor cells, allowing for diagnostic imaging and localization of these tumors.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T03:36:12.464Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Diagnostic imaging of neuroendocrine tumors (carcinoid tumors, gastroenteropancreatic neuroendocrine tumors)"},{"name":"Localization of somatostatin receptor-positive tumors"}]},"trialDetails":[{"nctId":"NCT00442533","phase":"PHASE2, PHASE3","title":"Safety and Efficacy Study of In-111 Pentetreotide to Treat Neuroendocrine Tumors","status":"COMPLETED","sponsor":"Radio Isotope Therapy of America","startDate":"2005-08","conditions":"Neuroendocrine Tumors","enrollment":200},{"nctId":"NCT01869725","phase":"PHASE2","title":"Comparative Study of Sensitivity of Ga-DOTATOC PET vs Octreoscan SPECT + CT","status":"COMPLETED","sponsor":"Sue O'Dorisio","startDate":"2013-04-01","conditions":"Adult Medulloblastoma, Childhood Medulloblastoma, Neuroblastoma","enrollment":68},{"nctId":"NCT02546388","phase":"NA","title":"Somatostatin Receptor Imaging in Patients With Suspected Cardiac Sarcoidosis","status":"COMPLETED","sponsor":"Marcelo F. Di Carli, MD, FACC","startDate":"2015-10","conditions":"Sarcoidosis","enrollment":17},{"nctId":"NCT02465112","phase":"PHASE3","title":"Metabolic Radiotherapy After Complete Resection of Liver Metastases in Patient With Digestive Neuroendocrine Tumor","status":"TERMINATED","sponsor":"GERCOR - Multidisciplinary Oncology Cooperative Group","startDate":"2015-09","conditions":"Digestive Neuroendocrine Tumors, Metabolic Radiotherapy, Resection","enrollment":4},{"nctId":"NCT00944372","phase":"PHASE4","title":"Study to Evaluate the Effect of Age (Geriatric) and Kidney Function on the Safety, Efficacy and Pharmacokinetics of OctreoScan in Patients Who Have New or Recurrent Tumors","status":"TERMINATED","sponsor":"Mallinckrodt","startDate":"2003-07","conditions":"Solid Tumors","enrollment":150},{"nctId":"NCT02078843","phase":"PHASE1, PHASE2","title":"Diagnostic Accuracy of Gallium-68-DOTATATE PET/CT Compared to Indium-111-pentetreotide Scintigraphy (SPECT/CT) for Gastroenteropancreatic Neuroendocrine Tumors","status":"TERMINATED","sponsor":"Insel Gruppe AG, University Hospital Bern","startDate":"2014-03","conditions":"Gastroenteropancreatic Neuroendocrine Tumors","enrollment":54},{"nctId":"NCT01099228","phase":"NA","title":"Combination Targeted Radiotherapy in Neuroendocrine Tumors","status":"COMPLETED","sponsor":"David Bushnell","startDate":"2006-09","conditions":"Neuroendocrine Tumors","enrollment":2},{"nctId":"NCT00002947","phase":"PHASE1","title":"Indium In 111 Pentetreotide in Treating Patients With Refractory Cancer","status":"TERMINATED","sponsor":"Yale University","startDate":"1996-10","conditions":"Brain and Central Nervous System Tumors, Childhood Langerhans Cell Histiocytosis, Gastrointestinal Carcinoid Tumor","enrollment":35}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["NeuroendoMedix"],"phase":"marketed","status":"active","brandName":"Indium-111 pentetreotide","genericName":"Indium-111 pentetreotide","companyName":"Radio Isotope Therapy of America","companyId":"radio-isotope-therapy-of-america","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Indium-111 pentetreotide is a radiolabeled somatostatin analog that binds to somatostatin receptors on neuroendocrine tumor cells, allowing for diagnostic imaging and localization of these tumors. Used for Diagnostic imaging of neuroendocrine tumors (carcinoid tumors, gastroenteropancreatic neuroendocrine tumors), Localization of somatostatin receptor-positive tumors.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}